Unified company culture enhances efficiency.
– Claude is accelerating model development.
– AI shows promise in drug design and diagnostics.
– Healthcare improvements are expected from AI advancements.
– Organizational unity is key to sustaining growth.
▸ Full transcript
I would say two things. The first is, you know, we have a unified company. We have a unified culture. You know, I think we've gotten, you know, grown larger while still being incredibly efficient. Everyone's still being on the same page, like just the cultural and organizational unity. I would say that's the biggest factor. And I would say the second biggest factor is Claude itself. That we're now using Claude to help, you know, develop our models and, you know, make them more efficient and quickly develop products. There's all kinds of new practices you have to develop. You know, we're still new at it, but, you know, it's producing a lot of acceleration and increasingly producing reliable acceleration. And so those are the two factors I would point to. Will you tell me the most wild thing you've seen AI do? I think some of the wildest stuff I've seen is around biology and medicine. I've seen a number of cases, including Daniela, actually, where Claude diagnosed a medical problem that, you know, a bunch of fancy doctors had missed. And on the biology side, the models are starting to get surprisingly good at tasks like drug design or computational chemistry or things like that. And I'm just like, wow, as someone who used to be a biology, I look at it and I'm like, wow, that's hard. You need a lot of training to do that. And like, Claude is getting good at it. And that's one area where I think we're going to get a hell of a lot of benefit. That's the positive for AI. We're going to get these huge, enormous benefits. Life is going to get better, the quality of human experience is going to get better. A century of scientists.
Analysis
The company has achieved significant cultural and organizational unity, which has contributed to its efficiency and growth. Additionally, the use of Claude is accelerating model development and enhancing product reliability, particularly in fields like biology and medicine.
Smart investors should note the potential of AI in drug design and computational chemistry, as demonstrated by Claude's ability to diagnose medical issues overlooked by professionals. This capability suggests that AI could lead to substantial advancements in healthcare, improving the quality of human experience significantly.